Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Sarepta Therapeutics今日宣布与Arrowhead ...

Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Sales & Marketing category. The reliance of Arrowhead ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...

周三，Piper Sandler调整了对Arrowhead Pharma (NASDAQ:ARWR)股票的展望，将12个月目标价从之前的$62下调至$45，同时维持对该股票的增持评级。这一重新评估是在Arrowhead宣布与Sarepta Therapeutics建立重要战略合作伙伴关系后做出的，该合作涉及多个TRiM项目。

Sarepta Therapeutics今天早些时候披露了与Arrowhead的新合作关系，收购了四个临床阶段的管线项目，涵盖神经肌肉、肺部和中枢神经系统（CNS）疾病等多个治疗领域。此外，该交易还包括三个临床前CNS项目和六个发现阶段项目。

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...